Comparative impact on islet isolation and transplant outcome of the preservation solutions institut georges lopez-1, university of Wisconsin, and celsior

Transplantation

Volumn 93, Issue 7, 2012, Pages 703-708

  Niclauss, Nadja ^a   Wojtusciszyn, Anne ^a,b   Morel, Philippe ^a   Demuylder Mischler, Sandrine ^a   Brault, Coralie ^c,d,e   Parnaud, Geraldine ^a   Ris, Frederic ^a   Bosco, Domenico ^a   Badet, Lionel ^f   Benhamou, Pierre Yves ^g   Berney, Thierry ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

^f UNIVERSITÉ DE LYON   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Islet graft function; Islet isolation; Islet transplant; Preservation solution

Indexed keywords

C PEPTIDE; CELSIOR; GLUCOSE; INSTITUT GEORGES LOPEZ 1 SOLUTION; INSULIN; PRESERVATION SOLUTION; UNCLASSIFIED DRUG; UNIVERSITY OF WISCONSIN SOLUTION;

ADULT; AGE; ARTICLE; BETA SCORE; BODY MASS; C PEPTIDE GLUCOSE RATIO; CELL FUNCTION; CONTROLLED STUDY; CRYOPRESERVATION; DONOR AGE; FEMALE; FOLLOW UP; GRAFT PRESERVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; ISOLATION PROCEDURE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; ORGAN WEIGHT; PANCREAS ISLET BETA CELL; PANCREAS ISLET ISOLATION; PANCREAS ISLET TRANSPLANTATION; PANCREAS WEIGHT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADENOSINE; ADULT; ALLOPURINOL; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-PEPTIDE; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS; DISACCHARIDES; ELECTROLYTES; FEMALE; GLUTAMATES; GLUTATHIONE; HEMOGLOBIN A, GLYCOSYLATED; HISTIDINE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MANNITOL; MIDDLE AGED; ORGAN PRESERVATION; ORGAN PRESERVATION SOLUTIONS; RAFFINOSE; RETROSPECTIVE STUDIES; TIME FACTORS; TISSUE AND ORGAN HARVESTING; TISSUE CULTURE TECHNIQUES; TREATMENT OUTCOME;

EID: 84859264224     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182476cc8     Document Type: Article

References (32)

1. Nanji SA, Shapiro AM. Advances in pancreatic islet transplantation in humans. Diabetes Obes Metab 2006; 8: 15
2. Nano R, Clissi B, Melzi R, et al. Islet isolation for allotransplantation: Variables associated with successful islet yield and graft function. Diabetologia 2005; 48: 906
3. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginaldose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830
4. Ploeg RJ, Goossens D, Sollinger HW, et al. Efficacy of 48-hour pancreas preservation with UW solution in the dog allograft model. Transplant Proc 1988; 20: 1026
5. Southard JH, Belzer FO. Organ preservation. Annu Rev Med 1995; 46: 235
6. Baertschiger RM, Berney T, Morel P. Organ preservation in pancreas and islet transplantation. Curr Opin Organ Transplant 2008; 13: 59
7. Stewart ZA, Cameron AM, Singer AL, et al. Histidine- tryptophanketoglutarate (HTK) is associated with reduced graft survival in pancreas transplantation. Am J Transplant 2009; 9: 217
8. Vega JD, Ochsner JL, Jeevanandam V, et al.Amulticenter, randomized, controlled trial of Celsior for flush and hypothermic storage of cardiac allografts. Ann Thorac Surg 2001; 71: 1442
9. Thabut G, Vinatier I, Brugière O, et al. Influence of preservation solution on early graft failure in clinical lung transplantation. Am J Respir Crit Care Med 2001; 164: 1204
10. Cavallari A, Cillo U, Nardo B, et al. A multicenter pilot prospective study comparing Celsior and University of Wisconsin preserving solutions for use in liver transplantation. Liver Transpl 2003; 9: 814
11. Faenza A, Catena F, Nardo B, et al. Kidney preservation with University of Wisconsin and Celsior solution: A prospective multicenter randomized study. Transplantation 2001; 72: 1274
12. Boggi U, Vistoli F, Del Chiaro M, et al. Pancreas preservation with University of Wisconsin and Celsior solutions: A single-center, prospective, randomized pilot study. Transplantation 2004; 77: 1186
13. Hubert T, Gmyr V, Arnalsteen L, et al. Influence of preservation solution on human islet isolation outcome. Transplantation 2007; 83: 270
14. Badet L, Ben Abdennebi H, Petruzzo P, et al. Effect of IGL-1, a new preservation solution, on kidney grafts (a pre-clinical study). Transpl Int 2005; 17: 815
15. Codas R, Petruzzo P, Morelon E, et al. IGL-1 solution in kidney transplantation: First multi-center study. Clin Transplant 2009; 23: 337
16. Ben Mosbah I, Rosello-Catafau J, Franco-Gou R, et al. Preservation of steatotic livers in IGL-1 solution. Liver Transpl 2006; 12: 1215
17. Dondero F, Paugam-Burtz C, Danjou F, et al. A randomized study comparing IGL-1 to the University of Wisconsin preservation solution in liver transplantation. Ann Transplant 2010; 15: 7
18. Ben Abdennebi H, Elrassi Z, Scoazec JY, et al. Evaluation of IGL-1 preservation solution using an orthotopic liver transplantation model. World J Gastroenterol 2006; 12: 5326
19. SklavosMM,Bertera S, Tse HM, et al. Redox modulation protects islets from transplant-related injury. Diabetes 2010; 59: 1731
20. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37: 413
21. Bucher P, Mathe Z, Morel P, et al. Assessment of a novel twocomponent enzyme preparation for human islet isolation and transplantation. Transplantation 2005; 79: 91
22. Ricordi C, Gray DW, Hering BJ, et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat 1990; 27: 185
23. Niclauss N, Sgroi A, Morel P, et al. Computer-assisted digital image analysis to quantify the mass and purity of isolated human islets before transplantation. Transplantation 2008; 86: 1603
24. Kempf MC, Andres A, Morel P, et al. Logistics and transplant coordination activity in the GRAGIL Swiss-French multicenter network of islet transplantation. Transplantation 2005; 79: 1200
25. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318
26. Toso C, Baertschiger R, Morel P, et al. Sequential kidney/islet transplantation: Efficacy and safety assessment of a steroid-free immunosuppression protocol. Am J Transplant 2006; 6: 1049
27. Badet L, Benhamou PY, Wojtusciszyn A, et al. Expectations and strategies regarding islet transplantation: Metabolic data from the GRAGIL 2 Trial. Transplantation 2007; 84: 89
28. Benhamou PY, Milliat-Guittard L, Wojtusciszyn A, et al. Quality of life after islet transplantation: Data from the GRAGIL 1 and 2 trials. Diabet Med 2009; 26: 617
29. Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230
30. Faradji RN, Monroy K, Messinger S, et al. Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant 2007; 7: 303
31. Ryan EA, Paty BW, Senior PA, et al. Beta-score: An assessment of betacell function after islet transplantation. Diabetes Care 2005; 28: 343
32. Caumo A, Maffi P, Nano R, et al. Transplant estimated function: A simple index to evaluate beta-cell secretion after islet transplantation. Diabetes Care 2008; 31: 301.